Pan-AKT inhibitors that are currently in clinical testing include capivasertib (AZD5363), MK-2206 and ipatasertib (GDC-0068), with preclinical data showing increased sensitivity in various PTEN-deficient cancer lines and xenograft models (including prostate cancer) [208,209,210]. The gene discussed is AKT1; the disease is cancer.